8-K - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

424B3 - MetaVia Inc. (0001638287) (Filer)

EFFECT - MetaVia Inc. (0001638287) (Filer)

S-8 - MetaVia Inc. (0001638287) (Filer)

POS AM - MetaVia Inc. (0001638287) (Filer)

10-K - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

SCHEDULE 13G - MetaVia Inc. (0001638287) (Subject)

CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025 in Amsterdam, the Netherlands.

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks Additional Cohorts Being Added to Determine Maximum Tolerated Dose CAMBRIDGE, Mass., April 22, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today report

 With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dL and Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose Maximum Waist Circumference Reduction of 3.9 Inches and Mean Reduction of 1.6 Inches Demonstrates Strong Signal of Glucagon Efficacy at Day 33 at 32 mg Dose Additional Cohorts Being Added to Determine Maximum Tolerated Dose Planned Phase 1 Part 3 to Include Wegovy® Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary End

Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect $16.0 Million in Cash at End of Fourth Quarter Expected to Fund the Company Into the Third Quarter of 2025 CAMBRIDGE, Mass., March 20, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.

CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's manag

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1December 4, 2024 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go ba

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1December 4, 2024 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go bac

CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET. After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to [email protected], or ask your questions during th

H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00